Cripto-1 抗体 (Internal Region)
TDGF1.3
适用: 人
ELISA, WB
宿主: 兔
Polyclonal
unconjugated
1 image
(5 references)-
- 抗原 See all Cripto-1 (TDGF1.3) products
- Cripto-1 (TDGF1.3) (Teratocarcinoma-Derived Growth Factor 1, Member 3 (TDGF1.3))
-
抗原表位
- Internal Region
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This Cripto-1 antibody is un-conjugated
-
应用范围
- ELISA, Western Blotting (WB)
- 产品特性
- Concentration Definition: by UV absorbance at 280 nm
- 免疫原
- This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to an sequence of human Cripto-1 protein.
- 亚型
- IgG
-
anti-Teratocarcinoma-Derived Growth Factor 1, Member 3 (TDGF1.3) (Internal Region) antibody
TDGF1.3 适用: 人 ELISA 宿主: 山羊 Polyclonal unconjugated
-
- 应用备注
- This affinity purified antibody has been tested for use in ELISA and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 21 kDa in size corresponding to Cripto-1 by western blotting in the appropriate cell lysate or extract. Cripto-1 is reported as a 188 amino acid protein with a molecular weight of 21.1 kDa.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 0.66 mg/mL
- 缓冲液
- 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
- 储存液
- Sodium azide
- 注意事项
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C
-
-
: "Cripto-1 vaccination elicits protective immunity against metastatic melanoma." in: Oncoimmunology, Vol. 5, Issue 5, pp. e1128613, (2016) (PubMed).
: "Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi." in: Oncology letters, Vol. 12, Issue 2, pp. 1349-1354, (2016) (PubMed).
: "Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients." in: Translational oncology, Vol. 6, Issue 6, pp. 732-41, (2014) (PubMed).
: "The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics." in: Cell cycle (Georgetown, Tex.), Vol. 12, Issue 9, pp. 1450-6, (2013) (PubMed).
: "Cancer hallmarks in induced pluripotent cells: new insights." in: Journal of cellular physiology, Vol. 225, Issue 2, pp. 390-3, (2010) (PubMed).
-
: "Cripto-1 vaccination elicits protective immunity against metastatic melanoma." in: Oncoimmunology, Vol. 5, Issue 5, pp. e1128613, (2016) (PubMed).
-
- 抗原
- Cripto-1 (TDGF1.3) (Teratocarcinoma-Derived Growth Factor 1, Member 3 (TDGF1.3))
- 别名
- Cripto-1 TDGF1 (TDGF1.3 产品)
- 背景
-
This antibody is designed, produced, and is suitable for Cancer, Immunology and Nuclear Signaling research. Human Cripto-1 (CR-1), also known as Teratocarcinoma-derived growth factor 1 (TDGF1), is a member of the epidermal growth factor (EGF)-GFC family and has been implicated in both embryogenesis and carcinogenesis. During early vertebrate development, CR-1 functions as a co-receptor for Nodal, a transforming growth factor b (TGFb) family member, and is essential for mesoderm and endoderm formation and anterior-posterior and left-right axis establishment. In adult tissues, CR-1 is expressed at a low level in all stages of mammary gland development, and expression increases during pregnancy and lactation. Over-expression of CR-1 in mouse mammary epithelial cells leads to their transformation in vitro, and when injected in mammary glands, CR-1 produces ductal hyperplasias.
Synonyms: Cripto1 antibody, Cripto1 growth factor antibody, Epidermal growth factor like cripto protein CR1 antibody, TDGF 1 antibody - 基因ID
- 6997, 4507425
- UniProt
- P13385
-
You are here:
